Clear Harbor Asset Management LLC Acquires Shares of 18,726 Boston Scientific Corporation $BSX

Clear Harbor Asset Management LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 18,726 shares of the medical equipment provider’s stock, valued at approximately $799,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BSX. First Nebraska Trust Co bought a new position in Boston Scientific during the second quarter valued at approximately $4,915,000. Bank of Nova Scotia bought a new position in Boston Scientific during the second quarter valued at $56,496,000. Kirtland Hills Capital Management LLC bought a new position in Boston Scientific during the 2nd quarter valued at about $416,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Boston Scientific in the second quarter worth approximately $1,314,000. Finally, Alta Advisers Ltd purchased a new stake in Boston Scientific in the second quarter worth $247,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on BSX. Jefferies Financial Group dropped their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Wells Fargo & Company reduced their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research note on Thursday, July 30th. Finally, Mizuho lowered their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 194,522 shares of company stock valued at $9,385,210 in the last three months. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $50.39 on Monday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market cap of $73.03 billion, a PE ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The business’s fifty day simple moving average is $46.34 and its 200-day simple moving average is $57.62.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.